vs
Apellis Pharmaceuticals, Inc.（APLS）与Nutex Health, Inc.（NUTX）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Nutex Health, Inc.的1.3倍（$199.9M vs $151.7M），Nutex Health, Inc.净利率更高（7.8% vs -29.5%，领先37.3%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -41.1%），Nutex Health, Inc.自由现金流更多（$69.0M vs $-14.3M），过去两年Nutex Health, Inc.的营收复合增速更高（50.0% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Nutex Health是一家总部位于美国得克萨斯州休斯敦的营利性医疗企业，核心业务为运营各类医疗机构，是美国本土医疗领域的专业运营机构，致力于为当地市场提供相关医疗服务与场地运营支持。
APLS vs NUTX — 直观对比
营收规模更大
APLS
是对方的1.3倍
$151.7M
营收增速更快
APLS
高出35.2%
-41.1%
净利率更高
NUTX
高出37.3%
-29.5%
自由现金流更多
NUTX
多$83.3M
$-14.3M
两年增速更快
NUTX
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $151.7M |
| 净利润 | $-59.0M | $11.8M |
| 毛利率 | — | 30.4% |
| 营业利润率 | -25.6% | 20.4% |
| 净利率 | -29.5% | 7.8% |
| 营收同比 | -5.9% | -41.1% |
| 净利润同比 | -62.2% | -80.8% |
| 每股收益（稀释后） | $-0.40 | $2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSNUTX
| Q4 25 | $199.9M | $151.7M | ||
| Q3 25 | $458.6M | $267.8M | ||
| Q2 25 | $178.5M | $244.0M | ||
| Q1 25 | $166.8M | $211.8M | ||
| Q4 24 | $212.5M | $257.6M | ||
| Q3 24 | $196.8M | $78.8M | ||
| Q2 24 | $199.7M | $76.1M | ||
| Q1 24 | $172.3M | $67.5M |
净利润APLSNUTX
| Q4 25 | $-59.0M | $11.8M | ||
| Q3 25 | $215.7M | $55.4M | ||
| Q2 25 | $-42.2M | $-17.7M | ||
| Q1 25 | $-92.2M | $21.2M | ||
| Q4 24 | $-36.4M | $61.6M | ||
| Q3 24 | $-57.4M | $-8.8M | ||
| Q2 24 | $-37.7M | $-364.0K | ||
| Q1 24 | $-66.4M | $-364.0K |
毛利率APLSNUTX
| Q4 25 | — | 30.4% | ||
| Q3 25 | — | 57.8% | ||
| Q2 25 | — | 51.2% | ||
| Q1 25 | — | 55.9% | ||
| Q4 24 | — | 55.0% | ||
| Q3 24 | — | 27.8% | ||
| Q2 24 | — | 29.7% | ||
| Q1 24 | — | 15.1% |
营业利润率APLSNUTX
| Q4 25 | -25.6% | 20.4% | ||
| Q3 25 | 48.7% | 48.7% | ||
| Q2 25 | -18.6% | 13.8% | ||
| Q1 25 | -50.0% | 38.1% | ||
| Q4 24 | -12.3% | 44.4% | ||
| Q3 24 | -24.0% | 12.3% | ||
| Q2 24 | -14.7% | 7.0% | ||
| Q1 24 | -36.0% | 2.1% |
净利率APLSNUTX
| Q4 25 | -29.5% | 7.8% | ||
| Q3 25 | 47.0% | 20.7% | ||
| Q2 25 | -23.6% | -7.3% | ||
| Q1 25 | -55.3% | 10.0% | ||
| Q4 24 | -17.1% | 23.9% | ||
| Q3 24 | -29.2% | -11.2% | ||
| Q2 24 | -18.9% | -0.5% | ||
| Q1 24 | -38.5% | -0.5% |
每股收益（稀释后）APLSNUTX
| Q4 25 | $-0.40 | $2.34 | ||
| Q3 25 | $1.67 | $7.76 | ||
| Q2 25 | $-0.33 | $-2.95 | ||
| Q1 25 | $-0.74 | $3.33 | ||
| Q4 24 | $-0.30 | $11.56 | ||
| Q3 24 | $-0.46 | $-1.72 | ||
| Q2 24 | $-0.30 | $-0.07 | ||
| Q1 24 | $-0.54 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $185.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $329.4M |
| 总资产 | $1.1B | $918.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSNUTX
| Q4 25 | $466.2M | $185.6M | ||
| Q3 25 | $479.2M | $166.0M | ||
| Q2 25 | $370.0M | $96.7M | ||
| Q1 25 | $358.4M | $84.7M | ||
| Q4 24 | $411.3M | $40.6M | ||
| Q3 24 | $396.9M | $46.9M | ||
| Q2 24 | $360.1M | $40.8M | ||
| Q1 24 | $325.9M | $30.0M |
总债务APLSNUTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSNUTX
| Q4 25 | $370.1M | $329.4M | ||
| Q3 25 | $401.2M | $317.2M | ||
| Q2 25 | $156.3M | $235.3M | ||
| Q1 25 | $164.2M | $176.9M | ||
| Q4 24 | $228.5M | $132.4M | ||
| Q3 24 | $237.1M | $60.4M | ||
| Q2 24 | $264.3M | $62.7M | ||
| Q1 24 | $266.7M | $63.0M |
总资产APLSNUTX
| Q4 25 | $1.1B | $918.5M | ||
| Q3 25 | $1.1B | $964.5M | ||
| Q2 25 | $821.4M | $841.0M | ||
| Q1 25 | $807.3M | $761.9M | ||
| Q4 24 | $885.1M | $655.3M | ||
| Q3 24 | $901.9M | $438.5M | ||
| Q2 24 | $904.5M | $422.4M | ||
| Q1 24 | $831.9M | $404.3M |
负债/权益比APLSNUTX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $70.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $69.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 45.5% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | 5.95× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $245.6M |
8季度趋势，按日历期对齐
经营现金流APLSNUTX
| Q4 25 | $-14.2M | $70.4M | ||
| Q3 25 | $108.5M | $99.5M | ||
| Q2 25 | $4.4M | $27.3M | ||
| Q1 25 | $-53.4M | $51.0M | ||
| Q4 24 | $19.4M | $54.0K | ||
| Q3 24 | $34.1M | $6.8M | ||
| Q2 24 | $-8.3M | $13.3M | ||
| Q1 24 | $-133.0M | $3.1M |
自由现金流APLSNUTX
| Q4 25 | $-14.3M | $69.0M | ||
| Q3 25 | $108.3M | $99.2M | ||
| Q2 25 | $4.4M | $26.5M | ||
| Q1 25 | $-53.4M | $50.9M | ||
| Q4 24 | $19.3M | $-341.0K | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | $-8.4M | $12.7M | ||
| Q1 24 | $-133.3M | $2.3M |
自由现金流率APLSNUTX
| Q4 25 | -7.1% | 45.5% | ||
| Q3 25 | 23.6% | 37.0% | ||
| Q2 25 | 2.5% | 10.9% | ||
| Q1 25 | -32.0% | 24.0% | ||
| Q4 24 | 9.1% | -0.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | -4.2% | 16.7% | ||
| Q1 24 | -77.3% | 3.4% |
资本支出强度APLSNUTX
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 0.0% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率APLSNUTX
| Q4 25 | — | 5.95× | ||
| Q3 25 | 0.50× | 1.80× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.40× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
